Acquisition Growth IBA Dosimetry recently expanded its footprint in the US and imaging capabilities by acquiring Radcal Corporation, signaling momentum in strengthening its dosimetry and X-ray imaging solutions. This creates cross-sell opportunities to Radcal’s existing customers and expands service and support reach.

Integrated QA Platform The company has a track record of launching integrated QA platforms such as myQA iON, indicating a shift toward end-to-end QA solutions. This presents upsell potential to customers seeking unified software and hardware for radiation therapy quality assurance.

Global Sales Reach Headquartered in Germany with subsidiaries in the US and China, IBA Dosimetry already operates across key markets. This regional presence can be leveraged to pursue hospitals and clinics looking for local support, faster implementation, and regional training.

Clinical Confidence Positioning emphasizes precision in radiotherapy and imaging QA to minimize errors and ensure exact dose delivery. This strong value proposition aligns with ongoing hospital priorities for patient safety, enabling value-based conversations and budget justifications for QA investments.

Financial Scale Entry With reported revenue in the 1 to 10 million USD range and a specialized niche in dosimetry, there is an opportunity to target mid-sized cancer centers and regional networks that require high-end QA solutions but have budget constraints, offering scalable packages and phased deployments.